ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: health insurance

The Pros & Cons of AI

Thomas R. Collins  |  November 5, 2025

As the uses for artificial intelligence grow within rheumatology, so do the benefits and the concerns about the technology. In a session at ACR Convergence 2025, two experts discuss the research on both sides of the debate.

Filed under:ACR ConvergenceMeeting ReportsTechnology Tagged with:ACR Convergence 2025AIartificial intelligenceclinical decision making

Meet New ACR President William (Will) F. Harvey

Leslie Mertz, PhD  |  October 29, 2025

Incoming ACR President Will Harvey shares his strategy for fighting reimbursement cuts, funding threats & workforce shortages through advocacy & member engagement.

Filed under:ACR ConvergenceFrom the CollegePresident's PerspectiveProfiles Tagged with:Access to medicationACR Convergence 2025ACR presidentAdvocacyDr. William (WILL) F. HarveyLegislation & AdvocacyReimbursementResearch Fundingworkforce shortage

Rheumatology Influencers: Dr. Hirsh Advocates for Physicians & Patients

Linda Childers  |  October 8, 2025

Dr. Marc Hirsch reflects on a career dedicated to advocating for physicians, providing patient-centered care & advancing medical education.

Filed under:GuidanceLegislation & AdvocacyPractice SupportProfiles Tagged with:Dr. Marc HirshMedicare Physician Fee Schedule (MPFS)physician payment reformPrivate practiceRheumatology Influencersscope of practice

What Clinicians Should Know About Midfoot Osteoarthritis

Yvonne M. Golightly, PT, MS, PhD, Jill Halstead, BSc, MSc, PhD, MRCPod, John B. Arnold, PhD, Lara S. Chapman, MSc, BPod, Catherine J. Bowen, PhD, BPod, Marian T. Hannan, DSc, MPH, Hylton B. Menz, PhD, BPod, Kade L. Paterson, PhD, BPod, BAppSci(Hons) & Martin J. Thomas, PhD, MCSP  |  October 8, 2025

Midfoot OA experts offer an overview of a common, but under-recognized, form of OA, & discuss quality of life impacts, treatments, clinical evaluation procedures & the critical need for further research.

Filed under:ConditionsGuidanceInterprofessional PerspectiveOsteoarthritis and Bone DisordersResearch Rheum Tagged with:DisparitiesExercisefootimagingmidfoot oteoarthritisNSAIDsorthoticsPainpodiatryquality of life

Rheumatology Influencers: Dr. Dave Has a Passion for Giving Back

Linda Childers  |  September 9, 2025

Dr. Amish Dave discusses how his volunteer, advocacy & public outreach work stem from his greater commitment to community & helping others.

Filed under:CareerLegislation & AdvocacyPractice SupportProfessional TopicsProfilesWorkforce Tagged with:AdvocacyDr. Amish J. Davefellowshiphealth disparitiesLeadershipprior authorizationpublic healthRheumatology InfluencersVolunteerworkforce shortage

3 AC&R Study Summaries: Avoidable RA Hospitalizations, Psoriasis to Psoriatic Arthritis Transition, & Neighborhood Conditions in Childhood Lupus

Arthritis Care & Research  |  September 8, 2025

New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.

Filed under:ConditionsPsoriatic ArthritisResearch RheumRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:AC&RBiomarkersC-reactive proteinCardiovascular diseasechildhood-onset SLEcomorbiditiesDisparitieshospitalizedPediatric RheumatologyPsA Resource CenterPsoriasisRA Resource CenterReading RheumSLE Resource Centersocioeconomic

How the Experts Treat Sjögren’s Disease

Samantha C. Shapiro, MD  |  August 26, 2025

With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.

Filed under:Biologics/DMARDsConditionsDrug UpdatesSjögren’s Disease Tagged with:Clinical Practice GuidelinesDry eyeDry MouthfatigueHYDROXYCHLOROQUINEInterstitial Lung DiseaseMethotrexateneuropathyshared decision makingSjögren’s Disease supplement

Medical Liability Reform Position Statement Now Addresses Harmful Payer Policies, Telemedicine Authorization & Patient Compensation

Leslie Mertz, PhD  |  August 23, 2025

The largest changes include additions that address harmful payer policies, telemedicine authorization and patient compensation funds.

Filed under:American College of RheumatologyLegislation & AdvocacyPractice Support Tagged with:ACR position statementsCommittee on Rheumatologic Care (CORC)liability

UHC Formulary Change Impacts Coverage for Ustekinumab

From the College  |  August 23, 2025

Effective Sept. 1, the brand name drug Stelara will no longer be covered on the UnitedHealthcare commercial plan prescription drug list.

Filed under:Drug UpdatesInsurance Tagged with:ustekinumab

White Bagging: A ‘Prescription for Disruption’ in Rheumatologic Care

From the College  |  August 22, 2025

In a recent op-ed published by MedCity News, rheumatologist and ACR Insurance Subcommittee Chair Michael Feely, MD, delivers a powerful critique of the insurance practice known as white bagging, calling it a “prescription for disruption” that threatens the quality and timeliness of patient care.

Filed under:Insurance Tagged with:ACR Insurance Subcommittee (ISC)white bagging

  • « Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 118
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences